Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Ozempic® (Semaglutide s.c.) in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 30 Nov 2022 Planned End Date changed from 1 Aug 2024 to 31 Dec 2024.
- 30 Nov 2022 Planned primary completion date changed from 1 Aug 2024 to 31 Dec 2024.
- 14 May 2021 Planned number of patients changed from 200000 to 600000.